Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cenerimod in moderate-to-severe systemic lupus erythematosus
2022-002814-17Phase 3Active
- Sponsor
- Idorsia
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing cenerimod 4 mg + background therapy with placebo + background therapy (2 arms). Primary endpoint: Change in modified SLEDAI-2K score at Month 12. Started Oct 2022; status: active.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-002814-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002814-17.